GHK-Cu in Special Populations: Route and Evidence Matter

“Special Populations” Is Not One Risk Category

The legacy page bundled transplant recipients, people with HIV, autoimmune disease, kidney disease, liver disease, pregnancy, children, and older adults into a single protocol. It then supplied laboratory panels and monitoring intervals without a GHK-Cu clinical study or guideline.

A route-aware evidence review starts with the regulator's actual finding:

“Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities.”

The issuer is the U.S. Food and Drug Administration on its current compounding-risk page, in the “Bulk drug substances nominated but withdrawn” table, GHK-Cu injectable row. The statement concerns a potential product and route risk. It does not establish that an adverse event occurred, provide a dose, or imply FDA endorsement.

FDA adds that human data are limited. That is the governing evidence boundary for an injectable special-population page.

The Route-Population Evidence Matrix

The matrix does not flatten every group into a prohibition. It shows why the legacy “candidate selection” framework was not evidence based.

What the Current Human Study Can—and Cannot—Answer

NCT07437586 is a recruiting Phase 2, randomized, vehicle-controlled study of topical 0.1% GHK-Cu gel on standardized skin wounds. It plans to enroll 60 healthy adults and has no results posted.

Its public eligibility criteria and design exclude the questions this page receives:

• it is not an injection study;
• it does not study Wilson disease or advanced organ disease;
• it does not establish pregnancy or pediatric safety;
• it does not test transplant, HIV, or cancer outcomes; and
• it cannot yet provide results because none are posted.

A trial registry is evidence that a question is being studied, not evidence that the intervention works or is safe.

Wilson Disease Is a Copper-Handling Question

The 2022 American Association for the Study of Liver Diseases guidance explains that reduced ATP7B function decreases hepatocellular copper excretion into bile, leading to hepatic copper accumulation and injury. Copper can later deposit in the brain, kidneys, and cornea.

That guidance is about Wilson disease diagnosis and management; it does not evaluate GHK-Cu. Its relevance is narrower and more important: Wilson disease cannot be treated as a generic “high-risk group” in an online peptide protocol.

The food-and-supplement interaction audit explains why oral copper and zinc facts do not become injectable timing rules. The GHK-Cu cancer-risk review separates angiogenesis experiments from human cancer outcomes, and the excess-exposure guide provides a product-and-route record for urgent assessment.

Figure 2

Wilson disease in NIDDK's words: copper that cannot leave the body, and treatment that removes it

Text version of this diagram

1. Normal copper handling: The liver releases extra copper into bile, which carries it out of the body through the digestive tract.
2. In Wilson disease: Inherited ATP7B gene mutations: the liver releases less copper into bile, and extra copper stays in the body.
3. Where it builds up: The liver, the brain and other organs. In the eyes it causes Kayser-Fleischer rings.
4. Treatment is lifelong: Chelating agents such as penicillamine and trientine remove copper. Zinc stops the intestines absorbing copper. Maintenance treatment keeps copper from building up again.
5. Where GHK-Cu fits: GHK-Cu is a copper-peptide complex. NIDDK's pages do not address it, which is why its use in Wilson disease belongs with the treating liver specialist.

A Product-and-Context Intake Is More Useful Than a Dose Table

Before any risk interpretation, identify:

1. Product: exact label, source, lot, concentration, ingredients, and whether it is a cosmetic or compounded drug.
2. Route: intact skin, damaged skin, post-procedure use, microneedling, or injection.
3. Purpose: cosmetic appearance, wound care, or another intended use.
4. Population detail: the actual diagnosis, disease control, organ function, pregnancy stage, age, or transplant status.
5. Concurrent treatment: immunosuppressants, cancer therapy, copper chelators, minerals, and other injections.
6. Decision: prospective use, current symptoms, product-quality concern, or an exposure error.

These fields do not create a recommendation. They stop unlike scenarios from being treated as one.

Why Mechanism Cannot Fill the Clinical Gap

GHK-Cu has been studied in fibroblasts, animal wounds, delivery models, and small aesthetic trials. A 2026 systematic review found 20 eligible studies, 18 of them preclinical and two randomized clinical trials. The review called for larger controlled trials with standardized formulations, dosing, and delivery routes (PMID 42619529).

That evidence can support a research rationale. It cannot define a safe injected dose for a transplant recipient, a pregnancy monitoring plan, or an exception for a child.

The Responsible Bottom Line

There is no single GHK-Cu “special-population protocol.” The responsible output is an evidence map showing which clinical questions remain unanswered and why route, product identity, and the underlying condition must stay visible.

Medical review of this revision is pending. FDA, AASLD, ClinicalTrials.gov, trial sponsors, and study authors do not endorse GHK-Cu, HealthRX.com, or this page.